Syngene International Ltd

SYNN.IN

$8.43

Closing

▼-1.32%

1D

▲0.16%

YTD

Market cap

$3.38B

52 week high

$10.32

52 week low

$6.91

Volume

795,692

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$3.38B

Analysts' Rating

BUY

Price Target (Mean)

Unable to collect data for some field(s).

Total Analysts

1

P/E

56.43

Operating Margin

17.58%

Beta

0.99

Revenue Growth (Annual)

13.79%

52 week high

$10.32

52 week low

$6.91

Div. Yield

0.07%

EPS Annual Growth

23.06

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Syngene International Limited is an India-based integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent’s portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.